A Delaware jury ordered Gilead Sciences Inc. (GILD) to pay Merck & Co. (MRK) $2.54 billion of royalties in a patent lawsuit, Reuters reported Thursday.

The jury found a Merck patent on hepatitis C drugs was valid, the report said.

Full story at http://www.reuters.com/article/us-gilead-sciences-merck-co-verdict-idUSKBN1442U9

Write to nymonitoring@dowjones.com

(END) Dow Jones Newswires

December 15, 2016 17:46 ET (22:46 GMT)

Copyright (c) 2016 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Merck Charts.
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Merck Charts.